This review explores the clinical hepatic pathology associated with the use of nonsteroidal
antiinflammatory drugs (NSAIDs), possible cellular and molecular mechanisms of injury, and …

Although the immune system is capable of mounting a response against many cancers, that
response is insufficient for tumor eradication in most patients due to factors in the tumor …

Immune evasion in cancer is increasingly recognized as a contributing factor in the failure of
a natural host antitumor immune response as well as in the failure of cancer vaccine trials. …

Background and Objective Immune escape by tumors can occur by multiple mechanisms,
each a significant barrier to immunotherapy. We previously demonstrated that upregulation of …

We searched for cell-surface-associated proteins overexpressed on B cell chronic
lymphocytic leukemia (CLL) to use as therapeutic antibody targets. Antibodies binding the …

Monoclonal antibodies (mAbs) have been used for decades as tools to probe the biology
and pharmacology of receptors in cells and tissues. They are also increasingly being …

CD200 is an immunosuppressive molecule overexpressed in multiple hematologic
malignancies such as B cell chronic lymphocytic leukemia, multiple myeloma, and acute myeloid …

Multiple cancer vaccine trials have been carried out using ex vivo generated autologous
dendritic cells (DCs) loaded with tumor antigen before readministration into patients. Though …

Previous work demonstrates that the reactive acyl glucuronide of the nonsteroidal antiinflammatory
drug diclofenac forms selective protein adducts in the liver, which may play a causal …

The nonsteroidal antiinflammatory drug diclofenac can bind irreversibly to hepatocellular
proteins via its acyl glucuronide metabolite. In view of a possible involvement of these protein …